On Friday, drug manufacturer Novo Nordisk warned in a news release that the FDAs decision means that making or selling a knockoff compounded drug that is essentially a copy of Ozempic or Wegovy is illegal. The company has already filed more than 100 lawsuits related to copycat semaglutide products, most under claims of false advertising or deceptive and unfair trade practices
The FDAs Pharmacy Compounding Advisory Committee backed BPC-157, KPV and TB-500 by 8 to 6 with one abstention, and MOTS-c by 7 to 5 with two abstentions, according to Pharmaceutical Executives tally of the meeting
Notably, semaglutide pharmacokinetic results after IcoSema administration were essentially similar between the two studies
We talk about how you are eating, not just what
Services offering meals below 20g protein are insufficient for GLP-1 users trying to preserve muscle
Clin Exp Pharmacol Physiol